Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
United StatesIPO:
18 May 2016Website:
http://www.pulsebiosciences.comNext earnings report:
28 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 20 Nov 2024 21:02:14 GMTDividend
Analysts recommendations
Institutional Ownership
PLSE Latest News
MIAMI--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced positive preliminary results from its first-in-human feasibility study using Nanosecond Pulsed Field Ablation for the treatment of benign thyroid nodules. Dr. Stefano Spiezia presented these excellent results today at the 2024 American Thyroid Association Annual Meeting. The preliminary data demonstrate.
Pulse Biosciences Inc. (NASDAQ:PLSE ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Philip Taylor - Investor Relations Burke Barrett - President & CEO Michael Koffler - VP of Finance Conference Call Participants Anthony Petrone - Mizuho Group Operator Greetings, and welcome to the Second Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
NEW YORK , Aug. 1, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Pulse Biosciences, Inc. (NASDAQ: PLSE) on behalf of the company's shareholders. The investigation seeks to determine whether Pulse Bioscience's directors breached their fiduciary duties in connection with recent corporate actions.
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q3 2023 Earnings Conference Call November 13, 2023 12:00 PM ET Company Participants Philip Taylor - IR Kevin Danahy - President and CEO Darrin Uecker - CTO and Director Mitchell Levinson - Chief Strategy Officer Michael Koffler - VP of Finance Bob Duggan - Chairman Conference Call Participants Operator Greetings, and welcome to the Pulse Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced it will now report financial results for the third quarter of 2023 before market opens on Monday, November 13, 2023. Company management will now host a corresponding conference call beginning at 9:00am PT / 12:00pm ET. Invest.
Pulse Biosciences Inc. (NASDAQ:PLSE ) Q2 2023 Results Conference Call August 10, 2023 4:30 PM ET Company Participants Philip Taylor - IR Kevin Danahy - Chief Executive Officer Darrin Uecker - CTO & Director Mitchell Levinson - Chief Strategy Officer Michael Koffler - Director of Finance Bob Duggan - Chariman of the Board of Pulse Biosciences Operator Greetings, and welcome to Pulse Biosciences' Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Trip Taylor - Investor Relations Kevin Danahy - President & Chief Executive Officer Darrin Uecker - Chief Technology Officer Mike Koffler - Vice President of Finance Robert Duggan – Executive Chairman Conference Call Participants Robert Lovgren – Medical Hope Productions Operator Good afternoon, ladies and gentlemen and thank you for standing by. Welcome to the Pulse Biosciences First Quarter 2023 Earnings Conference Call.
Pulse Biosciences Inc. (NASDAQ:PLSE ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Trip Taylor – Investor Relations Kevin Danahy – President and Chief Executive Officer Darrin Uecker – Chief Technology Officer Robert Duggan – Executive Chairman Conference Call Participants Robert Lovgren – Medical Hope Productions James Hollingsworth – Private Investor Operator Ladies and gentlemen, greetings, and welcome to the Pulse Biosciences' Fourth Quarter 2022 Earnings Conference Call. At this time all participants lines are in a listen-only mode.
What type of business is Pulse Biosciences?
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
What sector is Pulse Biosciences in?
Pulse Biosciences is in the Healthcare sector
What industry is Pulse Biosciences in?
Pulse Biosciences is in the Medical Instruments & Supplies industry
What country is Pulse Biosciences from?
Pulse Biosciences is headquartered in United States
When did Pulse Biosciences go public?
Pulse Biosciences initial public offering (IPO) was on 18 May 2016
What is Pulse Biosciences website?
https://www.pulsebiosciences.com
Is Pulse Biosciences in the S&P 500?
No, Pulse Biosciences is not included in the S&P 500 index
Is Pulse Biosciences in the NASDAQ 100?
No, Pulse Biosciences is not included in the NASDAQ 100 index
Is Pulse Biosciences in the Dow Jones?
No, Pulse Biosciences is not included in the Dow Jones index
When was Pulse Biosciences the previous earnings report?
No data
When does Pulse Biosciences earnings report?
The next expected earnings date for Pulse Biosciences is 28 March 2025